Typhoid vaccine study probes gut immunity secrets
NCT ID NCT03970304
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how the typhoid vaccine changes the immune system and bacteria in the gut. About 87 healthy adults getting a routine colonoscopy will either receive the vaccine before the procedure, after, or not at all. Researchers will analyze blood, tissue, and stool samples to understand the body's response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Vivotif Typhoid Oral Vaccine (Ty21a)
- What this could lead to
- If successful, this could help design better typhoid vaccines and improve understanding of how vaccines interact with gut health.
- What could go wrong
- This is an early-stage observational study, not testing a new treatment. Results may not lead to direct health benefits or apply to broader populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPHOID VACCINATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Universtiy of Maryland, Baltimore, Center for Vaccine Development and Global Health
Baltimore, Maryland, 21201, United States